DTILNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends May 21
PRECISION BIOSCIENCES INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$6.19+0.42 (+7.28%)
Close on Oct 19, 2026
- Market cap
- $160.05M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2017 to 2025
Operating margin
-152.2%+300.1 pts over 5 years
Net margin
-133.4%+315.4 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -50.1% | +10.9% | +7.1% | – |
Returns and balance sheet
9 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -119.3% | -61.5% | |
| Return on assets | – | -56.6% | -31.4% | |
| Current ratio | – | 2.46 | 13.32 | |
| Interest coverage | – | – | -36.7× | |
| Capex to revenue | – | 20.7% | 0.2% | |
| Diluted shares | – | 2M | 13M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Precision Biosciences generated $265.01M from operations and spent $10.66M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$265.01M
Used
$10.66M
Capital expenditure$10.66M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-133.4%
×Asset turnover0.24×
×Equity multiplier1.96×
=Return on equity, FY2025-61.5%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -133.4% | 0.24× | 1.96× | -61.5% |
| FY2024 | 10.4% | 0.46× | 3.94× | 19.0% |
| FY2023 | -125.8% | 0.24× | 5.02× | -154.7% |
| FY2022 | -444.8% | 0.11× | 2.97× | -147.3% |
| FY2021 | -26.5% | 0.64× | 2.67× | -45.1% |
| FY2020 | -448.9% | 0.13× | 2.11× | -119.3% |
| FY2019 | -417.6% | 0.12× | 2.10× | -104.2% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
1of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$45.72M
- Cash generatingOperating cash flow above zero-$65.84M
- Return on assets improvedROA up on the prior year4.5% → -33.5%
- Earnings backed by cashOperating cash flow above net income-$65.84M vs -$45.72M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose6.34 → 13.32
- No dilutionShare count did not rise7M → 13M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.43 → 0.25